Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action

Metabolism: Clinical and Experimental

Volumn 52, Issue 9, 2003, Pages 1147-1152

  Courtney, C Hamish ^a,b   McCance, David R ^a,b   Atkinson, A Brew ^a,b   Bassett, Jonathan ^a,b   Ennis, Cieran N ^a,b   Sheridan, Brian ^a,b   Bell, Patrick M ^a,b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b Montalto Health Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; DOXAZOSIN; GLUCOSE; INSULIN; NITROPRUSSIDE SODIUM; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CENTRAL RETINA VEIN OCCLUSION; CLAMP; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INCIDENCE; INSULIN RESISTANCE; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0141682422     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00190-2     Document Type: Article

References (49)

1. Panza JA, Quyyumi AA, Brush JE, et al: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323:22-27, 1990
2. Linder L, Kiowski W, Buhler FR, et al: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 81:1762-1767, 1990
3. Shen DC, Shieh SM, Fuh MT, et al: Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metab 66:580-583, 1988
4. Ferrannini E, Buzzigoli G, Bonadonna R, et al: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
5. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
6. Cooke J, Tsao P: Is nitric oxide an endogenous antiatherogenic molecule? Arterioscler Thromb Vasc Biol 14:653-655, 1994
7. Weinberger MH: Antihypertensive therapy and lipids. Evidence, mechanisms and implications. Arch Intern Med 145:1103-1105, 1985
8. Neaton JD, Grimm RH Jr, Prineas RJ, et al: Treatment of mild hypertension study. Final results. JAMA 270:713-724, 1993
9. Giorda C, Appendino M: Effects of doxazosin, a selective α 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism 42:1440-1442, 1993
10. Andersson P-E, Johansson J, Berne C, et al: Effect of selective α1 and β1-adreno-receptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 8:219-226, 1994
11. Kageyama S, Yamamoto J, Mimura A, et al: Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther 15:829-837, 1993
12. McAllister AS, Atkinson AB, Johnston GD, et al: Relationship of endothelial function to birth weight in humans. Diabetes Care 22:2061-2066, 1999
13. Hokanson DE, Sumner DS, Strandness DEJ: An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 22:25-29, 1975
14. Whitney RJ: The measurement of volume changes in human limbs. J Physiol (Lond) 121:1-27, 1953
15. Greenfield ADM, Patterson GC: Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (Lond) 125:508-524, 1954
16. 3H]glucose tracer in non-steady state. The role of a tritiated tracer impurity. Diabetologia 33:681-687, 1990
17. Harper R, Ennis C, Heaney AP, et al: A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 38:853-859, 1995
18. Somogyi M: Determination of blood sugar. J Biol Chem 160:69-73, 1945
19. Matthews JNS, Altman DG, Campbell MJ, et al: Analysis of serial measurements in medical research. BMJ 300:230-235, 1990
20. Roberts DH, Tsao Y, Breckenridge M: The reproducibility of limb blood flow measurements in human volunteers at rest and after exercise by using mercury-in-silastic strain gauge plethysmography under standardized conditions. Clin Sci 70:635-638, 1986
21. Steele R, Wall JS, De Bodo RC, et al: Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187:15-25, 1956
22. De Bodo RC, Steele R, Altszuler N, et al: On the hormonal regulation of carbohydrate metabolism: Studies with C14 glucose. Recent Prog Horm Res 19:445-488, 1963
23. Rooney DP, Neely RDG, Ennis CN, et al: Insulin action and hepatic glucose cycling in essential hypertension. Metabolism 41:317-324, 1992
24. Taddei S, Virdis A, Ghiadoni L, et al: Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilation in essential hypertensive patients. J Hypertens 116:447-456, 1998
25. Taddei S, Virdis A, Ghiadoni L, et al: Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 30:1606-1612, 1997
26. Lithell HOL: Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209, 1991
27. Hunter SJ, Harper R, Ennis CN, et al: Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension. J Hypertens 16:103-109, 1998
28. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526, 1987
29. Radomski MW, Palmer RM, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2:1057-1068, 1987
30. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777, 1989
31. Gorog P, Kovacs IB: Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated: Interference by oxidised low density lipoproteins. J Vasc Res 35:165-169, 1998
32. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651-4655, 1991
33. Seljeflot I, Arnesen H, Andersen P, et al: Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J Cardiovasc Pharmacol 34:584-588, 1999
34. Tojo A, Kobayashi N, Kimura K, et al: Effects of antihypertensive drugs on nitric oxide synthase activity in rat kidney. Kidney Int 49:S138-S140, 1996
35. Chait A, Gilmore M, Kawamura M: Inhibition of low density lipoprotein oxidation in vitro by the 6- and 7-hydroxy-metabolites of doxazosin, an α 1-adrenergic antihypertensive agent. Am J Hypertens 7:159-167, 1994
36. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 104:511-514, 2001
37. Rooney DP, Edgar JDM, Sheridan B, et al: The effects of low dose insulin infusions on the renin angiotensin and sympathetic nervous systems in normal man. Eur J Clin Invest 21:430-435, 1991
38. De Fronzo RA, Cooke CR, Andres R, et al: The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 55:845-855, 1975
39. Stout RW: Insulin and atheroma: 20 year perspective. Diabetes Care 13:631-654, 1990
40. Fuller JH, Shipley MJ, Rose G, et al: Coronary heart disease risk and impaired glucose tolerance. Lancet 1:1373-1376, 1980
41. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1:92-101, 1992
42. De Courten M, Ferrari P, Schneider M, et al: Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 44:457-462, 1993
43. UKPDS Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
44. Giorda C, Appendino M, Mason MG, et al: Alpha 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 44:673-676, 1995
45. 2+ channel antagonists and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 44:665-671, 1995
46. Baron AD, Steinberg HO, Chaker H, et al: Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 96:786-792, 1995
47. Utriainen T, Makimattila S, Virkamaki A, et al: Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 39:1477-1482, 1996
48. Utriainen T, Malmstrom R, Makimattila S, et al: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 38:555-564, 1995
49. Hunter SJ, Harper R, Ennis CN, et al: Skeletal muscle blood flow is not a determinant of insulin resistance in essential hypertension. J Hypertens 15:73-77, 1997